// App-Quantinova.ai

TPS5590 : Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Ben Tran

Principal Investigators

  • Lisa Horvath

  • Matthew Rettig

  • Karim Fizazi

  • Martijn P. Lolkema

  • Tanya B. Dorff

  • Richard Greil

  • Jean-Pascal H. Machiels

  • Karen A. Autio

  • Sylvie Rottey

  • Nabil Adra

  • Rohan Garje

  • Felicia Roncolato

  • Scott T. Tagawa

  • Shahrokh F. Shariat

  • Mark Salvati

  • Shirley Poon

  • Hosein Kouros-Mehr

Medical Centers

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Chris O'Brien Lifehouse, Camperdown, Australia

  • University of California, Los Angeles, VA Greater Los Angeles Healthcare System, Los Angeles, CA

  • Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France

  • Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands

  • City of Hope, Duarte, CA

  • IIIrd Medical Department, Paracelsus Medical University Salzburg

  • Salzburg Cancer Research Institute-CCCIT and Cancer Cluster, Salzburg, Austria

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Drug Research Unit Ghent, Ghent University, Ghent, Belgium

  • Indiana University School of Medicine, Indianapolis, IN

  • University of Iowa, Carver College of Medicine, Iowa City, IA

  • Scientia Clinical Research, Randwick, NSW, Australia

  • Weill Cornell Medicine, New York, NY

  • Medical University of Vienna, Vienna, Austria

  • Amgen Inc, Thousand Oaks, CA

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • 18F-fluorodeoxyglucose

  • Circulating tumor cells

  • Prostate specific antigen

  • Folate Hydrolase 1

Drug/Treatment

  • Pembrolizumab

  • Enzalutamide

  • CB-7598

  • taxane

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • NCT03792841

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved